About AVT23 AVT23 is a monoclonal antibody and proposed biosimilar to Xolair ® (omalizumab). AVT23 is an investigational compound and has not received regulatory approval in any country. Biosimilarity ...

Direct costs associated with IBD include ambulatory visits to gastroenterologists, emergency department visits, admissions ...

with adalimumab becoming the most commonly used b/tsDMARD. Researchers performed a serial cross-sectional study using ...

By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster ...

Experts predict that physicians may favour emerging biosimilar versions of Stelara over more effective originator IL-23 drugs ...

Celltrion USA has expanded access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-approved subcutaneous (SC) infliximab, to a significant share of the U.S. market ...

Treatment with CZP vs ADA may offer more consistent efficacy when used among patients with RA who have elevated RF levels.

(2696.HK) and Organon (NYSE: OGN) announced that the US Food and Drug Administration (FDA) has accepted the Biologic License Application (BLA) for HLX14, an investigational biosimilar of PROLIA/XGEVA ...